Genetic aberrations of upstream regulators, such as activating mutations of PI3K, Ras, b-Raf, loss of function mutations of PTEN, overexpression of EGFR, have been shown to be common in breast cancer and play an important role in its dysregulation [54–59]. This evidence concerns the gene EGFR and breast carcinoma.